Figure 1.

Tacrolimus dose-normalized concentration (Co : dose) up to 12 months post-transplantation of 108 renal transplant recipients according to their genotype. (A) Patients carrying CYP3A5*1 (n = 45) showed lower Co : dose when compared with patients homozygous CYP3A5*3 (n = 63), P < 0.0001. (B) Patients with non-TTT/TTT diplotype (n = 60) also showed lower Co :dose when compared with patients TTT/TTT (n = 12), P = 0.01. (C) Analysis considering CYP3A5 group stratified according to the ABCB1 genotype, patients carrying the *3-non-TTT/TTT diplotype (n = 34) showed lower Co : dose when compared with patients carrying *3-TTT/TTT diplotype (n = 10), P = 0.04. (D) Analysis considering CYP3A5 group stratified according to the ABCB1 genotype, patients carrying the *1-non-TTT/TTT diplotype (n = 26) showed higher Co : dose when compared with patients carrying *1-TTT/TTT diplotype (n = 2). The data, however, could neither be analyzed nor taken into consideration, due to the insufficient number of individuals. All data are expressed as median and percentiles